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A B S T R A C T
Atherosclerosis is the major underlying pathology of cardiovascular disease (CVD). The risk for CVD is increased
in women with a history of preeclampsia. Multiple studies have indicated that accelerated atherosclerosis un-
derlies this increased CVD risk. Furthermore, it has been suggested that endothelial dysfunction and in-
flammation play an important role in the increased CVD risk of women with preeclampsia. Rupture or erosion of
atherosclerotic plaques can induce the formation of thrombi that underlie the onset of acute clinical CVD such as
myocardial infarction and stroke. In relatively young women, cardiovascular events are mainly due to plaque
erosions. Eroded plaques have a distinct morphology compared to ruptured plaques, but have been understudied
as a substrate for CVD. The currently available evidence points towards lesions with features of stability such as
high collagen content and smooth muscle cells and with distinct mechanisms that further promote the pro-
thrombotic environment such as Toll Like Receptor (TLR) signaling and endothelial apoptosis. These suggested
mechanisms, that point to endothelial dysfunction and intimal thickening, may also play a role in preeclampsia.
Pregnancy is considered a stress test for the cardiovascular system with preeclampsia as an additional patho-
logical substrate for earlier manifestation of vascular disease. This review provides a summary of the possible
common mechanisms involved in preeclampsia and accelerated atherosclerosis in young females and highlights
plaque erosion as a likely substrate for CVD events in women with a history of preeclampsia.
1. Plaque erosion as a substrate for CVD in young women
Cardiovascular disease (CVD) often manifests through an occluding
thrombus as a consequence of a ruptured atherosclerotic plaque, or due
to arterial plaque erosion. Interestingly, the current hypothesis is that
the pathogenic mechanisms leading to either an atherosclerotic plaque
rupture or erosion are different. Most of our knowledge on the pa-
thology of plaque erosion is based on studies by the group of Virmani
and colleagues that has elegantly described plaque erosion as a me-
chanism of sudden death in autopsy studies from the 1980s onwards
(Farb et al., 1996; Kolodgie et al., 2001). Of all thrombi, approximately
31% is caused by plaque erosion (Jia et al., 2013; White et al., 2016).
Plaque erosion is especially common in young women (Farb et al.,
1996; Yahagi et al., 2015), and accounts for approximately 80% of all
thrombi in women under the age of 50 years (Campbell et al., 2014).
Plaque histology is different for plaque rupture and plaque erosion.
Ruptured plaques have a thin cap, macrophage infiltration, and lipid
core that exposes to the blood upon plaque rupture. Eroded plaques are
often characterized by a thick, intact cap and minor or no lipid core. In
addition, eroded plaques have an altered subendothelial matrix that
contains increased proteoglycans, hyaluronan, and smooth muscle cells.
Exposure of this matrix to platelets and blood coagulation factors can
cause thrombus formation (White et al., 2016). In the carotid artery,
histological analysis of atherosclerotic plaques consistently showed that
women display plaques with more stable features and less inflamma-
tion, suggestive of plaque erosion as a more prevalent substrate for CVD
as compared to men (Hellings et al., 2007; Vrijenhoek et al., 2014,
2013). Interestingly, the finding that symptomatic women reveal more
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stable plaques is independent of cardiovascular risk profile and clinical
presentation.
Eroded plaques, more common in women, show much less markers
of inflammation compared to unstable and ruptured plaques (Campbell
et al., 2014). Yet, inflammation may stimulate plaque erosion by ne-
gatively affecting the function and integrity of the endothelial lining of
the atherosclerotic plaque. Proteases capable of degrading the base-
ment membrane are produced in response to inflammation (White
et al., 2016). Different cytokines might have a role in the pathogenesis
of plaque erosion, potentially via the induction of endothelial dys-
function. Although plaque erosion has been understudied as compared
to plaque rupture, the potential mechanisms involved in the erosion of
the plaque have been extensively reviewed. These generally consist of
four components: (1) endothelial dysfunction and endothelial apoptosis,
(2) Toll Like Receptor signaling, (3) extracellular matrix changes and (4)
changes in platelet adhesion. With atherosclerotic plaque erosion being a
more common substrate for acute CVD in younger women, and pre-
eclampsia being a risk factor for CVD in women, we hypothesize that
preeclampsia may predispose to plaque erosion via shared pathophy-
siological mechanisms.
2. Preeclampsia and CVD risk, the link with atherosclerosis
Preeclampsia is a hypertensive pregnancy disorder complicating
around 1–5% of pregnancies and is characterized by de novo hy-
pertension and proteinuria, maternal organ dysfunction or uter-
oplacental dysfunction manifesting in the second half of pregnancy
(Baumwell and Karumanchi, 2007; Hernandez-Diaz et al., 2009). Pre-
eclampsia is a major cause of maternal and fetal morbidity and mor-
tality and may affect the health of the mother in the years directly
following preeclampsia. Observational studies have consistently shown
that women with former preeclampsia have a 2-fold increased risk to
develop CVD later in life. In particular, there is cumulating evidence
that preeclampsia predisposes to ischemic heart disease that occurs at
younger age than in women who have uncomplicated pregnancies. In a
study of 3658 women with preeclampsia, ≈ 50% developed future
hypertension with a 3.70 times higher risk compared to women with a
normotensive pregnancy (Bellamy et al., 2007). In addition, women
with a history of preeclampsia have a 2.2 times higher risk of devel-
oping ischemic heart disease. The risk of fatal ischemic heart disease
was increased in women with preeclampsia, and early onset pre-
eclampsia (before week 37) significantly added to this risk, resulting in
a relative risk of 7.71 (Bellamy et al., 2007). Similar, the risk of future
stroke was 1.81 times higher in women with preeclampsia compared to
normotensive pregnancy (Bellamy et al., 2007). Finally, the risk of fu-
ture thromboembolism is increased 1.79-fold for women with a pre-
eclamptic pregnancy, although absolute risk remains low (0.1% at 4.7
years after delivery) (Bellamy et al., 2007). Also, but to a lesser extent,
there is a relationship between the severity of preeclampsia when
presenting in pregnancy, and the long-term risk of CVD later in life.
Whereas for patients with mild preeclampsia a relative risk of CVD of
2.00 was found, this was 2.99 for patients with moderate preeclampsia
and 5.36 for patients with severe preeclampsia (McDonald et al., 2008).
The exact mechanisms by which preeclampsia increases future cardio-
vascular risk are unknown although multiple similarities between the
mechanisms responsible for CVD and preeclampsia are reported. For
example, risk factors for both CVD and preeclampsia in young women
include hypertension, obesity, insulin resistance, and hyperlipidemia
(Leslie and Briggs, 2016). However, these similarities do not fully ex-
plain the increased CVD risk in women with former preeclampsia as
adjustment for CVD risk factors shows that preeclampsia is an in-
dependent is risk factor for CVD (Berks et al., 2013; McDonald et al.,
2008). It has been hypothesized that women who experience pre-
eclampsia already have an increased vascular risk prior to developing
CVD. The exposed vascular stress during pregnancy causes the body to
reach the threshold for development of endothelial dysfunction,
vascular inflammation and hampered vascular remodeling with in-
sufficient placental oxygen supply, which have all been reported in the
presence of preeclampsia (Sattar and Greer, 2002). Later in life, vas-
cular risk factors rise for both the healthy population and women with a
history of preeclampsia, but women with a history of preeclampsia are
more likely to develop vascular disease earlier compared to the healthy
female population pointing to a lower threshold for stressors to elicit
vascular occlusive disease. (Powe et al., 2011; Sattar and Greer, 2002).
Several studies have revealed that endothelial dysfunction and angiogenic
imbalance are the first indicators of vascular damage in preeclampsia
patients. This in combination with the chronic inflammatory state in
preeclampsia patients may lead to acceleration of atherosclerosis after
preeclampsia.
3. Vascular dysfunction in preeclampsia
While atherosclerosis is a slowly developing progressive condition
that finds its origin in adolescence and progresses throughout life with
atherosclerotic plaques as a final stage, vascular changes such as acute
atherosis, occur relatively instantly in the placental blood vessels
during preeclampsia. Atherosis in the spiral arteries is characterized by
subendothelial lipid filled foam cells, fibrinoid necrosis of the arterial
wall, perivascular lymphocytic infiltration, and it is histologically si-
milar to early-stage atherosclerosis (Kim and Kim, 2015). In the spiral
artery remodeling study (SPAR) study, systematic screens of vascular
pathology in placental bed biopsy samples were related to CVD risk
factors in women with preeclampsia or normal pregnancy (Veerbeek
et al., 2016). They showed that in women with preeclampsia fewer of
the spiral arteries showed complete remodeling and the placenta con-
tained not as much infiltrated CD3+ T cells compared to health preg-
nancy. The authors speculate the latter may specifically relate to fewer
infiltrating regulatory T cells, which have the ability to control for
excessive inflammation. Besides it was suggested that the presence of
acute atherosis in the placental bed associated to an unfavorable lipo-
protein profile postpartum. Although this study provided valuable in-
sight into the link between placental bed disorders and cardiovascular
health, these findings remain to be established in the complete SPAR
study cohort (Veerbeek et al., 2016).
Carotid intima media thickness (cIMT) is a surrogate marker for
atherosclerosis burden that is assessed non-invasively and associated
with the presence of CVD. A recent meta-analysis showed that women
who experienced preeclampsia had significantly increased carotid in-
tima-media thickness compared to women without preeclampsia, both
at the time of diagnosis and in the first decade postpartum
(Grand'Maison et al., 2016; Milic et al., 2017). In addition, impaired
coronary flow reserve during preeclampsia has been documented.
These measures of vascular dysfunction have been correlated with
circulating levels of inflammatory biomarkers such as high sensitive C-
reactive protein (hs-CRP) as well (Ciftci et al., 2014). The time course of
this vascular dysfunction after preeclampsia has not been established
up to now. cIMT was increased the first year after severe preeclampsia,
but was no longer elevated approximately 5 years postpartum (Blaauw
et al., 2014). This suggests that, despite evident vascular dysfunction
during preeclampsia, vascular homeostasis may be restored after pre-
eclampsia (Blaauw et al., 2014). Despite the evident decrease in cIMT
after 5 years it remains to be confirmed that vascular homeostasis is
fully recovered. It may very well be that the endothelial integrity is not
fully restored or that the vasculature may remain more sensitized to
stress. As such the former preeclamptic vasculature may have an aug-
mented response to stress-related or inflammatory stimuli as seen in
atherosclerosis.
4. Hypoxia, oxidative stress and angiogenesis in preeclampsia
Endothelial dysfunction is caused by a combination of oxidative
stress, angiogenic and vasoresponsive imbalance, and inflammation
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(Table 1) (Lazdam et al., 2012). As a result, women with endothelial
dysfunction reveal decreased vasodilation (Knock and Poston, 1996;
Noori et al., 2010), increased arterial stiffness (Robb et al., 2009) and
atherosclerosis (Anastasakis et al., 2008) in the larger vessels. Skin
microvascular density (Hasan et al., 2002; Nama et al., 2012) and
placenta microvascular density (Uras et al., 2012) were found to be
decreased in women with preeclampsia, while others have shown that
vascular growth was not significantly affected in preeclampsia (Li et al.,
2015). A negative correlation in vasodilator response between the
macro and microcirculation has been suggested and this negative cor-
relation was also observed in women with preeclampsia (Agatisa et al.,
2004; Murphy et al., 2014; Yinon et al., 2010). Incomplete remodeling
of the uterine spiral arteries causes placental ischemia-reperfusion
episodes. During these episodes, reactive oxygen species are formed,
(Lazdam et al., 2012; Steegers et al., 2010). This leads to oxidative
stress (Sikkema et al., 2001), shown by increased levels of marker lipid
peroxide (Shaker and Sadik, 2013). Reactive Oxygen Species decrease
the bioavailability of pro-angiogenic nitric oxide (NO) via the sup-
pression of NO synthase (NOS). In addition, peroxynitrite is formed
when Reactive Oxygen Species and NO react. Peroxynitrate can in turn
oxidize DNA, proteins, and lipids. As a consequence, NO balance is
disturbed, which can result in impaired vasodilation and angiogenesis
(Matsubara et al., 2015). Other molecules that are upregulated by
oxidative stress are NF-κB and superoxides, resulting in further acti-
vation of anti-angiogenic (Lazdam et al., 2012) and pro-inflammatory
pathways (Goulopoulou and Davidge, 2015).
Another result from placental ischemia is an angiogenic imbalance
towards a more anti-angiogenic and vasoconstrictory state (Table 1)
(Lazdam et al., 2012). Vascular endothelial growth factor (VEGF) and
placental growth factor (PlGF) are important pro-angiogenic and va-
sodilatory molecules (Powe et al., 2011). Serum levels of PlGF (Levine
et al., 2004) and VEGF (Sezer et al., 2013) are decreased in women who
develop preeclampsia. Both VEGF and PlGF bind to VEGF-receptor 1,
also known as Flt-1 (Powe et al., 2011). In a healthy pregnancy, VEGF
and PlGF bind to Flt-1 on the endothelial cell surface, resulting in ac-
tivation of anticoagulant, vasodilatory, and proangiogenic pathways.
The soluble form of the Flt-1 receptor, sFlt-1, that is a natural antago-
nist for VEGF and PlGF, is increased in women with preeclampsia
(Levine et al., 2004). sFlt-1 binds VEGF and PlGF, thereby preventing
binding to endothelial cell-surface Flt-1 receptors. As a result of de-
creased binding to the Flt-1 receptor, the anticoagulant, vasodilatory,
and proangiogenic pathways are inhibited and endothelial cells become
dysfunctional (Hod et al., 2015; Karumanchi et al., 2005). In addition to
increased levels of sFlt-1, serum levels of soluble endoglin (sEng) were
also found to be increased in patients with preeclampsia (Levine et al.,
2006; Venkatesha et al., 2006). Endoglin is a TGF-β co-receptor highly
expressed on the membranes of activated endothelial cells (Goumans
et al., 2017). Membrane bound endoglin can either stimulate or inhibit
cellular responses downstream of TGF-β and of its family members, the
Bone Morphogenetic Protein (BMP) ligands. In endothelial cells en-
doglin stimulates angiogenesis (Lebrin et al., 2004). sEng has different
affinity for TGF-β and BMP. sEng interferes with TGF-β signaling by
trapping circulating TGF-β1. TGF-β signaling stimulates vasodilation
via the activation of NO (Venkatesha et al., 2006), stimulates vascular
Table 1
Overview of mechanisms of endothelial dysfunction and inflammation involved in atherosclerosis and preeclampsia.
Atherosclerosis Preeclampsia
Endothelial dysfunction ↑ ↑
Oxidative stress ↑ Plaque ↑ Placenta Sikkema et al., 2001
Reactive Oxygen Species ↑ Plaque Harrison et al., 2003; Li et al.,
2014b
↑ Placenta Lazdam et al., 2012; Steegers et al., 2010
NO imbalance ↑ Plaque Dimmeler et al., 2002 ↑ Placenta Matsubara et al., 2015
Superoxide ↑ Placenta Lazdam et al., 2012
NF-κB ↑ Plaque Li et al., 2014b ↑ Placenta Goulopoulou and David, 2015
Angiogenic imbalance
Pro-angiogenic ↑ ↓ Lazdam et al., 2012
VEGF ↑ Plaque Roncal et al., 2010 ↓ Systemic Sezer et al., 2013
PlGF ↑ Systemic,
Plaque
Roncal et al., 2010; Khurana et al.,
2005
↓ Systemic Levine et al., 2004
HIF-1α ↑ Plaque Aarup et al., 2016; Akhtar et al.,
2015
↑ Placenta Tal, 2012; Rajakumar et al., 2004
sFlt-1 ↑ Plaque Roncal et al., 2010 ↑ Systemic Levine et al., 2004
sEng ↑ Systemic,
Plaque
Nachtigal, 2012 ↑ Systemic Levine et al., 2006; Venkatesha et al., 2006
Vascular compliance
Vasodilation ↓ Systemic Knock and Poston, 1996; Noori
et al., 2010
↓ and ↑a Systemic Agatisa et al., 2004; Murphy et al., 2014; Yinon et al.,
2010
Arterial stiffness ↑ Systemic Robb et al., 2009 ↑ Systemic Robb et al., 2009
Microvascular density ↑ Plaque Depre et al.,1996; Zhang et al.,
1993
↓ Placenta Hasan et al., 2002; Nama et al., 2012; Uras et al., 2012
EndMT
Myofibroblasts ↑ Plaque Bostrom et al., 2016; Chen et al.,




Goumans et al., 2017; Goumans




Hansson, 2009 ↑ Systemic,
Placenta
Harmon et al., 2016
TLR ↑ Systemic, PBMC Bjorkbacka, 2006; Roshan et al.,
2016
↑ Placenta Li et al., 2016
Elsenberg et al., 2013 PBMC Van Rijn et al., 2016
IL-6 ↑ Systemic Ridker, 2016 ↓ and ↑ Systemic Stubert et al., 2016; Pinheiro et al., 2015
TNFα ↑ Systemic Zhang et al., 2009 ↓ and ↑ Systemic Ferguson et al., 2017; Udenze et al., 2015; Moreno-
Eutimio et al., 2014; Mudin et al., 2016; Taylor et al.,
2016
Placental Weel et al., 2016; Li et al., 2016; Azizieh and Raghupathy,
2015
a Decreased in macrovasculature and increased in microvasculature.
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homeostasis and can either stimulate or inhibit angiogenesis depending
on the context (Powe et al., 2011). As a result of increased sENG, NO
induced vasodilation, (Venkatesha et al., 2006) angiogenesis and vas-
cular homeostasis are diminished (Powe et al., 2011) in patients with
preeclampsia. TGF-β binds with very low affinity to sEng and likely
only does bind in the presence of a soluble TGFβ type II receptor while
sEng binds with high affinity to BMP9 and inhibits BMP9 induced sig-
naling (Gregory et al., 2014). Scavenging of BMP9 by sEng reduces the
BMP9 induced ET-1 vascular stability and hypertension (Park et al.,
2012) It has been suggested that hypoxia-inducible factor 1 subunit α
(HIF-1α) is responsible for the increased amounts of sEng and sFlt-1 in
preeclampsia (Tal, 2012). The hypoxic environment of the preeclamptic
placenta triggers the expression of HIF-1α, which indeed was increased
in the placenta of preeclamptic women (Rajakumar et al., 2004). In
pregnant mice, overexpression of HIF-1α increased the serum levels of
sFlt-1 and sEng and resulted in hypertension and proteinuria, both
hallmarks of preeclampsia. These human and animal data suggest that
HIF-1α plays an important role in the pathogenesis of preeclampsia via
the activation of antiangiogenic pathways (Tal, 2012; Tal et al., 2010).
This appears ambiguous, since HIF-1α normally activates the tran-
scription of VEGF (Forsythe et al., 1996), PlGF (Kelly et al., 2003), and
other hypoxia- and angiogenesis-associated proteins (Oka et al., 2014)
as a response to hypoxia. However, this increase is often brief. Long-
term upregulation of HIF-1α has been described in the pathology of
multiple diseases, including preeclampsia (Iriyama et al., 2015).
5. Hypoxia, oxidative stress and angiogenesis in atherosclerosis
and plaque erosion
Angiogenic imbalance is less well described in atherosclerosis than
in preeclampsia. General consensus is that plaque neovessels primarily
derive from the preexisting dense vessel network of the adventitial vaso
vasorum, rather than the arterial luminal (Depre et al., 1996; Zhang
et al., 1993) and increased neovascularization enhances atherosclerotic
plaque progression via increasing macrophage infiltration and vessel
wall thickening (Chistiakov et al., 2015; Moreno et al., 2012). In ad-
dition, the newly formed vessels can rupture, causing intraplaque he-
morrhage contributing in lipid rich necrotic core expansion and oxi-
dative stress (Moreno et al., 2012). Although VEGF levels are
sequentially increased with progressing atherosclerotic disease burden,
the exact role of VEGF in atherosclerosis remains unclear, both in hu-
mans and in animal models (Heinonen et al., 2013; Yla-Herttuala et al.,
2007). In atherosclerosis, PlGF expression has been shown to be in-
creased, especially in the shoulder region of the atherosclerotic plaque.
In early stages of the disease, treatment with anti-PlGF antibodies was
able to inhibit the inflammatory process and plaque progression. In
later stages of the disease, anti-PlGF antibody treatment had no effect
on the plaque development. This suggests that PlGF is primarily in-
volved in plaque development by inducing an inflammatory response
(Roncal et al., 2010; Sainz and Sata, 2010). Indeed, PlGF has been
shown to increase atherosclerotic development via the stimulation of
intimal thickening and macrophage accumulation (Khurana et al.,
2005). In addition to VEGF and PlGF, levels of Flt-1 are also increased
in the shoulder regions of the atherosclerotic plaque (Roncal et al.,
2010). The antagonist of VEGF and PlGF, sFlt-1 has been shown to
inhibit plaque formation, possibly via the inhibition of intraplaque
angiogenesis (Wang et al., 2011). These processes are opposite to those
witnessed in preeclampsia, where VEGF and PlGF levels are decreased
and sFlt-1 levels are increased, causing an anti-angiogenic environment
(Table 1). In plaque erosion, endothelial cell apoptosis is an important
part of the pathologic process. Deprivation of growth factors such as
VEGF contributes to this process (White et al., 2016). In addition, de-
creased levels of VEGF increase oxidative stress and apoptosis
(Dimmeler et al., 2002; Hulsmans and Holvoet, 2010). Although the
involvement of PlGF in plaque erosion has not yet been described, its
involvement is likely similar to that of VEGF. The role of sFlt-1 in
plaque erosion has also not been described yet. Given the function of
sFlt-1, increased levels of sFlt-1 would decrease VEGF and PlGF sig-
naling, thereby stimulating endothelial cell apoptosis and plaque ero-
sion. Another important protein in preeclampsia pathophysiology, en-
doglin, is also expressed by endothelial cells and smooth muscle cells in
atherosclerotic vessels. Endoglin expression is associated with plaque
neoangiogenesis, collagen deposition and thereby stabilizes the plaque
(Bot et al., 2009). Increased levels of sEng are proatherogenic via in-
hibition of endoglin function and inhibition of TGF-β signaling
(Nachtigal et al., 2012). HIF-1α is expressed by various cell types in the
atherosclerotic lesion and promotes the development and progression
of atherosclerosis (Aarup et al., 2016; Akhtar et al., 2015). Inhibition of
HIF-1α has been shown to decrease plaque size (Christoph et al., 2014),
reduce vascular inflammation (Akhtar et al., 2015; Liu et al., 2016) and
overall inhibit the development of atherosclerosis (Aarup et al., 2016;
Christoph et al., 2014; Liu et al., 2016). Although no studies reported a
role of sEng in plaque erosion, Matrix metalloproteinase 14 (MMP14)
polymorphism was found to be related to a lower risk of vulnerable
carotid plaque formation (Li et al., 2014a). Furthermore, sEng induced
Il-6 and NF-κB in endothelial cells, generating a pro-inflammatory state
of the cells (Varejckova et al., 2017). Finally, KLF6 was found to induce
MMP14 in endothelial cells, resulting in increased levels of sEng, and
reducing membrane bound Endoglin (Gallardo-Vara et al., 2016). Re-
duced endoglin levels on the endothelial cell surface renders them more
sensitive to endothelial to mesenchymal transition (EndMT).
6. Reactive oxygen species in atherosclerosis and preeclampsia
As well as in preeclampsia, endothelial dysfunction is a pivotal
process in the development of atherosclerosis. In preeclampsia, en-
dothelial dysfunction is characterized by oxidative stress, angiogenic
imbalance, and vasodilatory imbalance. Endothelial dysfunction has
also been described in plaque erosion. This endothelial dysfunction is
suggested to be paired with endoplasmic reticulum stress and en-
dothelial cell apoptosis causing detachment of the endothelial cell
layer, exposing the sub endothelial matrix and activating thrombus
formation (Hansson et al., 2015). Reactive Oxygen Species production
is increased by the common risk factors of preeclampsia and CVD, for
example hypertension, hypercholesterolemia, diabetes, cigarette
smoking, aging (Harrison et al., 2003; Li et al., 2014b). In preeclampsia,
this is further driven by excessive Reactive Oxygen Species production
in the placenta, and inadequate action of protective placental scaven-
ging enzymes e.g. superoxide dismutase (SOD) (Sikkema et al., 2001).
This sustained elevation of Reactive Oxygen Species levels leads to
oxidative stress, with endothelial dysfunction as a consequence (Sitia
et al., 2010). In addition, Reactive Oxygen Species stimulate in-
flammation via the activation NF-κB pathway and activation of the
macrophages in the plaque (Li et al., 2014b). In plaque erosion, Re-
active Oxygen Species cause the production of oxidized lipoproteins.
These lipoproteins induce apoptosis of endothelial cells, resulting in
plaque erosion (Dimmeler et al., 2002; Hulsmans and Holvoet, 2010).
In addition, Reactive Oxygen Species induced endothelial dysfunction
might induce the production and activation of proteases and matrix
metalloproteinases (MMP), which in turn can degrade the basement
membrane. Basement membrane degradation has been described as a
process involved in plaque erosion (White et al., 2016). Also, oxidative
stress causes a decrease in NO, thereby decreasing its anti-apoptotic
effect (Dimmeler et al., 2002).
7. Novel manifestations of endothelial dysfunction in
atherosclerosis
Another process that may add to the endothelial dysfunction seen in
both atherosclerosis and preeclampsia is endothelial to mesenchymal
transition (EndMT). Endothelial to mesenchymal transition (EndMT) is
a complex, dynamic and reversible biological process that can change
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endothelial cell integrity and can contribute to the pathogenesis of
many diseases including hypertensive disorder (Arciniegas et al., 2007).
EndMT can be stimulated by differences in several metabolic and in-
flammatory factors, which are all important in the pathogenesis of
atherosclerosis. EndMT is a common phenomenon in atherosclerotic
lesions, contributes to plaque progression and lesion calcification
(Bostrom et al., 2016; Chen et al., 2015), and is more common in ad-
vanced vulnerable plaques (Evrard et al., 2016). As such it has been
suggested that the presence of endMT may associate with clinical events
(Evrard et al., 2016) and that the process of endMT may be a promising
therapeutic target for atherosclerosis (Jackson et al., 2017).
8. Endothelial to mesenchymal transition (EndMT)
When endothelial cells undergo EndMT, they loosen cell-cell contact
and change from a cobblestone-like well-structured monolayer into a
more chaotic mesenchymal elongated phenotype. Endothelial cells
undergoing EndMT down-regulate their endothelial specific markers
like Pecam-1, VE-cadherin, and FLK-1, and start to express protein
characteristics for a mesenchymal gene signature cells such as α smooth
muscle actin (α-SMA), fibroblast specific protein-1 (FSP-1) and type I
collagen (Goumans and Ten Dijke, 2017). The EndMT derived me-
senchymal cells are often called myofibroblasts as they express both
smooth muscle cell and fibroblast specific genes. EndMT is initiated by
activation of the endothelium by e.g. inflammatory cytokines which
loosens the cell-cell contacts. One of the key regulators of the me-
senchymal transition is TGF-β in a variety of endothelial cells. TGF-β
can directly influence EndMT by the expression of the transcription
factors Snail and Slug, or indirectly by inducing EndMT regulating
microRNAs like microRNA-21 (Kumarswamy et al., 2012). Disturbed
flow, can induce a morphological switch in endothelial cells. En-
dothelial cells in high shear areas lose their primary cilia making them
more sensitive to TGF-β induced EndMT (Egorova et al., 2011; Hierck
et al., 2008; Sanchez-Duffhues et al., 2015). Also in the context of
atherosclerosis it has been shown that EndMT can be induced by shear
stress modifications (Mahmoud et al., 2017; Moonen et al., 2015) and
plaque foam cells can initiate EndMT trough the release of the che-
mokine CCL4/Macrophage Inflammatory Protein 1β (Yang et al.,
2017). As mentioned, these cells are prominent in atherosclerosis, due
to disturbed flow at the boundaries of the plaque (Sanchez-Duffhues
et al., 2015) with key functions including regulation of inflammation,
matrix and collagen production, and plaque structural integrity
(Table 1). 'Transitioning' cells are readily detected in human athero-
sclerotic plaques co-expressing endothelial and fibroblast/mesench-
ymal proteins, indicative of EndMT (Evrard et al., 2016).
9. Inflammation as common pathway for preeclampsia and
atherosclerotic plaque erosion
Besides endothelial dysfunction, inflammation is a major con-
tributor to the onset of preeclampsia and atherosclerosis (Hansson,
2009; Harmon et al., 2016). Endothelial dysfunction causes increased
adhesiveness and permeability of the endothelial layer allowing for
leukocytes and platelets to adhere and transmigrate through this da-
maged endothelium. In addition, the dysfunctional endothelium pro-
duces cytokines, vasoactive molecules, and growth factors. The in-
flammatory response initiated in preeclampsia shows many similarities
to the inflammatory response of atherosclerosis (Table 1). Athero-
sclerotic lesion formation is characterized by massive macrophage ac-
cumulation in the intimal area, but, as the lesion progresses, can ac-
tually contain almost all inflammatory cell types. The placentas of
preeclamptic women contain higher numbers of macrophages and the
infiltration of macrophages has been associated with impaired tropho-
blast infiltration (Ning et al., 2016). Similar to that observed in ather-
osclerosis, these macrophages are predominantly of the pro-in-
flammatory M1 like phenotype (Huang et al., 2008). The persisting
inflammatory response results in activation of macrophages and lym-
phocytes in the affected area where they release hydrolytic enzymes,
chemokines, cytokines, and growth factors. Although many cytokines
and chemokines have been implicated in the development of athero-
sclerosis and preeclampsia, here we review those most studied in both
pathologies.
9.1. Toll like receptors
Toll-like receptors (TLRs) are highly conserved receptors of the in-
nate immune arm that are instrumental in atherosclerotic plaque in-
flammation by recognizing pathogen- and damage-associated molecular
patterns that can be upregulated on, for example, tissue damage or cell
stress (Goulopoulou et al., 2016; Roshan et al., 2016; Seneviratne and
Monaco, 2015; Vink et al., 2004, 2002). In atherosclerosis, TLR func-
tion is traditionally linked to its effect on plaque macrophages and foam
cells, but nowadays it is also recognized that certain TLRs can modify
endothelial cell function (Salvador et al., 2016). TLR2 and TLR4 are
predominantly expressed in endothelial cells of the vascular wall and
have been associated to atherosclerotic lesion development in different
murine models (Bjorkbacka, 2006; Roshan et al., 2016). Genetic var-
iation in the TLR2 and TLR4 gene have been associated to early onset
preeclampsia (van Rijn et al., 2008; Xie et al., 2010), while the asso-
ciation of TLR2 and TLR4 SNPs to cardiovascular risk is debated on.
Genetic variations in the TLR4 gene, Asp299Gly and Thr399Ile have
been associated to increased risk for cardiovascular events (Boekholdt
et al., 2003; Edfeldt et al., 2004), that may be the consequence of
modified efficacy of statin treatment in the Asp299Gly carriers.
(Boekholdt et al., 2003). On the other hand, it has also been reported
that the TLR4 Asp299Gly variant associates to decreased CRP levels and
increased carotid artery compliance, suggesting that this variant may
also reduce cardiovascular risk (Hernesniemi et al., 2008; Kolek et al.,
2004). In an elegant study of Li and colleagues, first trimester primary
cytotrophoblast and first trimester decidual macrophages were isolated
during normal pregnancy and subsequently stimulated with LPS. Tro-
phoblast are placental epithelial cells that are important for proper
implantation of the fertilized eggs. Cytotrophoblasts can differentiate
into syncytiotrophoblast which are important in transport of nutrients
to the fetal system, or into extravillous trophoblast which are important
in uterine vasculature remodeling to ensure proper blood supply. De-
cidual macrophages are placenta specific macrophages that accumulate
in close proximity to the implantation site of spiral arteries with the
maternal uterine lining (decidua). Decidual macrophages play an im-
portant role in play important roles in spiral artery remodeling and
angiogenesis but also in extravillous trophoblast invasion and in mod-
ulation of the inflammatory response (Lash et al., 2016). LPS dose-de-
pendently induced cytokine release, including TNFα, IL-6 and IL-1β,
from trophoblasts. In addition, LPS stimulation inhibited trophoblast
invasion while it increased macrophage accumulation in a TLR4 de-
pendent manner (Li et al., 2016). In line with these findings it was
shown that the inflammatory response to the TLR ligands is stronger in
women with a history of preeclampsia and remain stronger over time
when compared to women without preeclampsia (van Rijn et al., 2016).
Similar effects were observed in patient with stable coronary artery
disease compared to healthy controls (Elsenberg et al., 2013).
9.2. Interleukin-6 (IL-6)
IL-6 predicts cardiovascular events and has been associated with
endothelial dysfunction and arterial stiffness (Ridker, 2016). IL-6 is
involved in the causal pathway of atherosclerotic disease progression.
The biological function of IL-6 is pleiotropic and includes increased
platelet production, differentiation, migration and proliferation of T
cells, migration and proliferation of smooth muscle cells, recruitment of
neutrophils and the production of matrix metalloproteinases (MMPs),
which are all processes driving the inflammatory process in
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atherosclerosis and preeclampsia. Experimental atherosclerosis studies
have shown that in absence of IL-6 atherosclerotic lesion development
in ApoE-/- mice is accelerated, which rather appeared to be a con-
sequence of increased plasma lipid levels and not of inflammation, as
the latter was decreased in IL-6 deficient animals (Schieffer et al.,
2004). Genetic variation in the IL6 gene is associated with reduced CVD
risk as shown in a large mendelian randomization study and a meta-
analysis (Collaboration et al., 2012; Interleukin-6 Receptor Mendelian
Randomisation Analysis et al., 2012). It has been suggested that genetic
variation in the promotor region of IL6 also is a genetic regulator of
early onset preeclampsia (Sowmya et al., 2015), while there is no as-
sociation to the IL6 SNPs described to be associated to cardiovascular
risk (Fan et al., 2017). In addition, although circulating IL-6 levels did
not predict for the onset of preeclampsia (Stubert et al., 2016), IL-6
levels were shown to be significantly increased in severe preeclampsia
as compared to normotensive pregnant women (Pinheiro et al., 2015).
Thus, IL-6 is a major player in several shared pathologic mechanisms of
both preeclampsia and atherosclerotic disease.
9.3. Tumor necrosis factor-α (TNFα)
TNFα is a classical inflammatory cytokine that is increased in pa-
tients with atherosclerosis (Zhang et al., 2009). It attributes to the de-
velopment of atherosclerosis by inducing endothelial dysfunction as a
consequence of decreased NOS expression and endothelial cell apop-
tosis (Grainger, 2007). In addition, TNFα increases oxidative stress,
inflammation and vascular remodeling. Data regarding circulating
TNFα levels in preeclampsia yielded conflicting results. Some studies
showed increased TNFα levels during all trimesters (Ferguson et al.,
2017; Udenze et al., 2015), or the last trimester only (Moreno-Eutimio
et al., 2014), while others have found TNFα levels to be unchanged or
even decreased in 2nd trimester preeclamptic pregnancy (Mundim
et al., 2016; Taylor et al., 2016). One prospective study even found that
TNFα levels, in combination with mean uterine artery doppler, could
have additional value in predicting women at risk for preeclampsia
(Gomaa et al., 2015). TNFα is expressed in trophoblasts and its ex-
pression is increased in the preeclamptic placenta, predominantly in
early preeclampsia (Weel et al., 2016). Exposure of Human primary
trophoblast to LPS increased TNFα production in these cells (Li et al.,
2016). In addition, mononuclear cells of women with preeclampsia
were more sensitive to stimulation with a mitogen or antigen and
consequently produced more TNFα (Azizieh and Raghupathy, 2015).
TNFα (G-308A) polymorphism is enriched in preeclampsia patients
(Tavakkol Afshari et al., 2016; Zhou et al., 2016) and presence of this
polymorphism increased disease risk (Zubor et al., 2014), again sug-
gestive of a genetic component in the inflammatory arm of pre-
eclampsia.
Despite the fact that the exact mechanisms involved in plaque
erosion are largely unknown, it is generally accepted that plaque ero-
sion mainly occurs in relatively stable plaques. These plaques are ty-
pically characterized by a low amount of plaque inflammation. As such,
it has been postulated that plaque inflammation may not be so im-
portant for plaque erosion. Systemic inflammatory responses however
may affect the process of plaque erosion directly, as a consequence of
promoting thrombus formation, or indirectly through induction of en-
dothelial dysfunction or apoptosis.
10. Future perspectives
In summary, many of the determinants that are involved in ather-
osclerotic plaque erosion are also observed in preeclampsia related
vascular disease (Fig. 1). The mechanisms that underlie the predis-
position of atherosclerotic CVD early in life in women with a history of
preeclampsia is poorly understood. The concept of a pre-existent low-
ered threshold to withstand vascular stressors is intriguing and posi-
tions pregnancy as a clinically relevant vascular stress test. Research on
the mechanisms leading to preeclampsia may also unravel the me-
chanisms that result in early manifestations of cardiovascular disease
with plaque erosion as the pathological substrate. If common me-
chanisms are unraveled it may well become reality that prevention of
arterial thrombosis in young females may be directed towards stabili-
zation of endothelial function and subsequent prevention of plaque
erosion.
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